MSpatient

Total Rating:
0 / 0

3 Comments

    • Fri Feb 22nd 15:45 PM | Rating: 0 0
      Commented on:
      Is Shire Eying Questcor as a Potential Takeover Target?
      Michael, where exactly did you get the numbers for a $125.0 million revenue estimate? Read any good (older) blogposts recently?
      View article »
    • Tue Dec 11th 21:46 PM | Rating: 0 0
      Commented on:
      Questcor: Undiscovered Biopharma Diamond in the Rough
      Convenient timing for such an enthusiastic article. Published on the same day which Questcor's Senior VP-Finance and CFO filed a SEC Form 4 reporting the sale of $1 million worth of stock last week.
      View article »
    • Tue Dec 11th 21:43 PM | Rating: 0 0
      Commented on:
      Questcor: The Non Orphan, Orphan Drug Company
      "Acthar is approved to reduce muscle spasms from multiple sclerosis..."

      Right from the start of the article, it is clear that Mr. Shulman doesn't really know what he is talking about. Acthar is FDA approved for treament of MS exacerbations which are not described as 'muscle spasms.' He is confusing 'Infantile Spasms' with 'Multiple Sclerosis.'


      "Technically, Acthar doesn't even have orphan drug status -- the company is applying for that to the FDA."

      Again, severely unresearched, inaccurate information. Acthar was awarded Orphan Drug Status in July 2003. What Questcor applied for is an FDA-approved indication for the treatment of 'Infantile Spasms' which is a rare form of epilepsy in children.


      "But the company is right that insurance companies and other payers won't let babies die and demand for Acthar hasn't fallen in the face of the price increase."

      The fact is that demand has fallen at least 30% since July, before the implementation of the 1500% price increase in August. It would be my guess that demand will not likely return to the same levels anytime soon. And Questcor is seeing about 90% insurance coverage.

      Consider this, on the same day that a SEC Form 4 was filed by the Senior VP-Finance and CFO of Questcor reporting sales of over $1 million worth of stock, two investor articles were published on the web. Interesting timing indeed.

      View article »
Loading...
Symbols:
Authors:
Quick Links:
Contribute an Article Become a Seeking Alpha Contributor

Transcripts

More Transcripts»